|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||35.93 - 37.40|
|52 Week Range||22.58 - 57.80|
|PE Ratio (TTM)||21.21|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||1.00 (2.70%)|
|1y Target Est||48.75|
A large part of investment returns can be generated by dividend-paying stock given their role in compounding returns over time. Over the past 9 years, PetMed Express Inc (NASDAQ:PETS) hasRead More...
Although the ongoing trade dispute between the United States and China can take a toll on sectors that are cyclical in nature, a few stocks promise stellar returns in 2018.
NEW YORK, April 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
PetMed Express Inc (NASDAQ:PETS), a online retail company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highsRead More...
Amazon's (AMZN) new partnership with Monoprix will allow the prime members to shop the grocer's products online via Prime Now app.
In an evolving retail space characterized by increased consumer demand, four stocks are expected to record significant earnings growth in 2018.
Companies that have significant growth prospects for profitability and returns can add tangible upside to your portfolio. PetMed Express and Weibo are examples of many potential outperformers that analysts areRead More...
For investors with a long-term horizon, examining earnings trend over time and against industry peers is more insightful than looking at an earnings announcement in one point in time. InvestorsRead More...
Expedia (EXPE) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
High-growth may be important to some investors, whereas steady dividend payments or great value for money may be a deciding factor for others. There are many factors that make upRead More...
Chimerix (CMRX) makes progress in Q4 through advancement with lead product candidate, brincidofovir. Revenues decline from lower reimbursable expenses regarding BARDA developmental contract.